PrognosDx, Accium team on histone biomarker tests

PrognosDx Health is combining its epigenetics technology with Accium BioSciences' accelerator mass spectronomy platform to develop predictive histone biomarker tests. The two companies hope to create tools that will help clinicians treat cancer. “We have identified specific studies that would help further define the developmental direction of various diagnostic tests and the potential benefits they may provide to specific patient populations," noted Accium president Ali Arjomand in a Genetic Engineering News report. Article

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.